Calcidiol and prostate cancer

Area of Science:

• Endocrinology
• Molecular Biology
• Oncology

Background:

• Epidemiological studies link serum calcidiol (25(OH)-Vitamin D3) to various cancers, including prostate cancer.
• Vitamin D metabolites, particularly calcitriol (1alpha,25(OH)2-Vitamin D3), have been traditionally considered the primary active forms.
• The precise mechanisms of vitamin D action in prostate cancer remain incompletely understood.

Purpose of the Study:

• To investigate the role and mechanisms of vitamin D metabolites in prostate stromal cells.
• To clarify whether calcidiol or calcitriol is the active form at physiological concentrations in the prostate.
• To review recent studies on vitamin D metabolism, growth factors, and fatty acid metabolism in the prostate.

Main Methods:

• Experimental studies on human primary prostate stromal cells.
• Assessing the biological activity of calcidiol and calcitriol at physiological concentrations.
• Gene expression analysis, including 1alpha-hydroxylase and 24-hydroxylase.
• Review of literature on vitamin D metabolism, growth factors, and fatty acid metabolism.

Main Results:

• Calcidiol (100-200 nM) demonstrated significant biological activity in prostate stromal cells, inhibiting cell growth.
• Calcitriol (100 pM) was found to be inactive in these cells at physiological concentrations.
• Calcidiol modulated the expression of key genes, including 1alpha-hydroxylase and 24-hydroxylase.

Conclusions:

• Calcidiol acts as an independent active hormone in prostate cells, regulating cell differentiation and proliferation.
• Calcitriol's primary role may be in calcium and phosphorus balance, not directly in prostate cell activity.
• Vitamin D's action in the prostate involves complex mechanisms including its metabolism, growth factors, and fatty acid metabolism.